Pauline Percier-Lehebel

After obtaining a master's degree in biology, biotechnology, and therapeutic research at the Faculty of Science in Nantes (France), Pauline Percier joined the laboratory of parasitology, supervised by Dr Carine Truyens at the Faculty of Medicine (Université Libre de Bruxelles, Belgium) as a research engineer. She developed a neonatal immunization model in mice to characterize a novel adjuvant molecule from the Trypanosoma cruzi parasite for a pediatric vaccination.
Pauline Percier did a PhD at Sciensano Institute (Belgium) in the Immune response, In vivo
team under the supervision of DrSc Olivier Denis to study how molds can counteract mycobacterial and allergic lung diseases through divergent immune mechanisms in mouse models.
Then, she did a postdoc at Sciensano Institute to characterize the innate and adaptive immune response against rabies induced by a new chimeric vaccine (Yellow fever-rabies) in a mouse model.
An expert in immunology and animal models, she joined InhaTarget Therapeutics, where she is responsible for the in vivo part of the preclinical studies. The objective is to demonstrate the efficacy of innovative and targeted dry powders for inhalation (DPI) in in vivo models in order to improve the treatment of lung cancer in humans.